This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Greenwald, J. A. Articles by Longaker, M. T. Search for Related Content PubMed PubMed Citation Articles by Greenwald, J. A. Articles by Longaker, M. T.

(American Journal of Pathology. 2001;158:441-452.)
© 2001 American Society for Investigative Pathology

Regular Article

In Vivo Modulation of FGF Biological Activity Alters Cranial Suture Fate

Joshua A. Greenwald^*, Babak J. Mehrara^*, Jason A. Spector^*, Stephen M. Warren, Peter J. Fagenholz, Lee P. Smith^*, Pierre J. Bouletreau, Francesca E. Crisera, Hikaru Ueno and Michael T. Longaker

From the Laboratory of Developmental Biology and Repair,^*
The Institute of Reconstructive Plastic Surgery, and The Department of Surgery, New York University Medical Center, New York, New York; the Department of Cardiology,
Molecular Cardiology Unit, Kyushu University School of Medicine, Fukuoka, Japan; and the Department of Surgery,
Stanford University School of Medicine, Stanford, California

Gain-of-function mutations in fibroblast growth factor receptors have been identified in numerous syndromes associated with premature cranial suture fusion. Murine models in which the posterior frontal suture undergoes programmed fusion after birth while all other sutures remain patent provide an ideal model to study the biomolecular mechanisms that govern cranial suture fusion. Using adenoviral vectors and targeted in utero injections in rats, we demonstrate that physiological posterior frontal suture fusion is inhibited using a dominant-negative fibroblast growth factor receptor-1 construct, whereas the normally patent coronal suture fuses when infected with a construct that increases basic fibroblast growth factor biological activity. Our data may facilitate the development of novel, less invasive treatment options for children with craniosynostosis.

This article has been cited by other articles:

				J. C. Barnard, A. J. Williams, B. Rabier, O. Chassande, J. Samarut, S.-y. Cheng, J. H. D. Bassett, and G. R. Williams Thyroid Hormones Regulate Fibroblast Growth Factor Receptor Signaling during Chondrogenesis Endocrinology, December 1, 2005; 146(12): 5568 - 5580. [Abstract] [Full Text] [PDF]

				Y. Tanimoto, M. Yokozeki, K. Hiura, K. Matsumoto, H. Nakanishi, T. Matsumoto, P. J. Marie, and K. Moriyama A Soluble Form of Fibroblast Growth Factor Receptor 2 (FGFR2) with S252W Mutation Acts as an Efficient Inhibitor for the Enhanced Osteoblastic Differentiation Caused by FGFR2 Activation in Apert Syndrome J. Biol. Chem., October 29, 2004; 279(44): 45926 - 45934. [Abstract] [Full Text] [PDF]

				M. K. Hajihosseini, M. D. Lalioti, S. Arthaud, H. R. Burgar, J. M. Brown, S. R. F. Twigg, A. O. M. Wilkie, and J. K. Heath Skeletal development is regulated by fibroblast growth factor receptor 1 signalling dynamics Development, January 15, 2004; 131(2): 325 - 335. [Abstract] [Full Text] [PDF]

				D. A. Stevens, C. B. Harvey, A. J. Scott, P. J. O'Shea, J. C. Barnard, A. J. Williams, G. Brady, J. Samarut, O. Chassande, and G. R. Williams Thyroid Hormone Activates Fibroblast Growth Factor Receptor-1 in Bone Mol. Endocrinol., September 1, 2003; 17(9): 1751 - 1766. [Abstract] [Full Text] [PDF]

				D. M. Ornitz and P. J. Marie FGF signaling pathways in endochondral and intramembranous bone development and human genetic disease Genes & Dev., June 15, 2002; 16(12): 1446 - 1465. [Full Text] [PDF]